Natalina Salmaso, PhD
Postdoctoral FellowAbout
Research
Publications
2025
Emerging autism and Fragile X syndrome treatments
Parkhill M, Salmaso N, D'Angiulli A, Lee V, Aguilar-Valles A. Emerging autism and Fragile X syndrome treatments. Trends In Pharmacological Sciences 2025 PMID: 40102109, DOI: 10.1016/j.tips.2025.02.004.Peer-Reviewed Original ResearchFragile X syndromeCore symptoms of autismSymptom-focused treatmentTreating core symptomsSymptoms of autismFragile X syndrome treatmentBiology of autismEndocannabinoid modulationCore symptomsDisorder heterogeneityX syndromeAutismPersonalized treatment approachesPharmacological interventionsTreatment approachesDisordersLate-phase trialsAnti-inflammatory approachesEndocannabinoidEffective therapyRecent trialsClinical trialsInterventionTrialsMicrobiome therapiesRace and ethnicity matter! Moving Parkinson’s risk research towards diversity and inclusiveness
Siddiqi S, Ortiz Z, Simard S, Li J, Lawrence K, Redmond M, Tomlinson J, Schlossmacher M, Salmaso N. Race and ethnicity matter! Moving Parkinson’s risk research towards diversity and inclusiveness. Npj Parkinson's Disease 2025, 11: 45. PMID: 40050644, DOI: 10.1038/s41531-025-00891-7.Peer-Reviewed Original ResearchComparative analysis of AAV serotypes for transduction of olfactory sensory neurons
Belfort B, Jia J, Garza A, Insalaco A, McGinnis J, Pekarek B, Ortiz-Guzman J, Tepe B, Chen H, Investigators A, Liu Z, Arenkiel B, Arenkiel B, Liu Z, Mollenhauer B, Penninger J, Rousseaux M, Saghatelyan A, Salmaso N, Stadelmann C, Schlossmacher M, Tomlinson J, Woulfe J, Wang Y, Chen Z, Jeong M. Comparative analysis of AAV serotypes for transduction of olfactory sensory neurons. Frontiers In Neuroscience 2025, 19: 1531122. PMID: 40018362, PMCID: PMC11865030, DOI: 10.3389/fnins.2025.1531122.Peer-Reviewed Original ResearchOlfactory sensory neuronsAAV serotypesSensory neuronsCentral nervous systemOptimal AAV serotypeAdeno-associated virusNervous systemGene therapyNasal inoculationSingle-nucleus RNA sequencingOdor informationNeuronal biologyNeuronsModel diseaseSerotypesConfocal imagingVolatile odorantsRNA sequencingSensory inputAAV1AAVSingle-nucleusTransductionTherapyTropism
2024
An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions
Lewis V, Rurak G, Salmaso N, Aguilar-Valles A. An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions. Trends In Neurosciences 2024, 47: 195-208. PMID: 38220554, DOI: 10.1016/j.tins.2023.12.004.Peer-Reviewed Original ResearchMajor depressive disorderEffects of ketamineTreatment-resistant major depressive disorderTherapeutic effect of ketamineSubanesthetic doses of ketamineKetamine's antidepressant actionAction of ketamineDose of ketamineAntidepressant actionCell type-specific mechanismsDepressive disorderSubanesthetic dosesRecreational drugsNeurotransmitter receptorsKetamineAntidepressantsCell-type-specific approachesTherapeutic effectEsketamineIntegrative viewCell typesDisordersBrainMolecular mechanismsSynapses
News
News
- August 16, 2013
Seven Yale investigators receive grants to pursue brain and behavior research
- November 26, 2012
42nd Annual Meeting of the Society for Neuroscience